News
04-08-2013, 12:54 AM
Nektar Therapeutics today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research Annual Meeting.
More... (http://www.news-medical.net/news/20130408/Nektar-Therapeutics-presents-positive-results-for-NKTR-214-at-AACR-Annual-Meeting.aspx)
More... (http://www.news-medical.net/news/20130408/Nektar-Therapeutics-presents-positive-results-for-NKTR-214-at-AACR-Annual-Meeting.aspx)